Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 8 5 W ELECTROLYTES versus AMINOSYN II 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN 8.5% W/ELECTROLYTES vs AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 8.5% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition. It provides essential and non-essential amino acids necessary for protein synthesis, tissue repair, and maintenance of nitrogen balance. Electrolytes are included to maintain acid-base balance and normal cellular function.
Aminosin II 4.25% in Dextrose 25% provides essential amino acids and dextrose for parenteral nutrition. Amino acids serve as building blocks for protein synthesis, while dextrose supplies a source of calories to prevent catabolism. The combination aims to maintain nitrogen balance and support metabolic functions.
Intravenous infusion: 500 mL to 1000 mL of 8.5% solution (42.5-85 g amino acids) once daily, infused at a rate not exceeding 100 mL/hour.
Administer as a continuous intravenous infusion. Typical adult dose: 1.0-1.5 g amino acids/kg/day (equivalent to approximately 23-35 mL/kg/day of AMINOSYN II 4.25% in DEXTROSE 25%) via central venous line. Adjust based on metabolic needs and tolerance.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for essential amino acids and 0.5-2 hours for non-essential amino acids, reflecting rapid distribution and metabolism in healthy adults. In renal or hepatic impairment, half-life may be prolonged.
Amino acids: 0.5-2 hours; dextrose: 1-4 hours in non-diabetic patients; context: reflects rapid uptake and metabolism
Amino acids are primarily eliminated via metabolism (deamination, transamination) and incorporation into proteins. Unmetabolized amino acids are excreted renally (approximately 5-10% of administered dose, depending on renal function and infusion rate). Fecal and biliary excretion are negligible (<1%).
Renal: >90% as amino acids and metabolites; biliary/fecal: minimal (<2%)
Category C
Category C
Amino Acid Solution
Amino Acid Solution